iogen Inc. shares rose 1.6% in afternoon trade after data from its Alzheimer's drug was leaked. Biogen has been the particular target of investor interest after the recent high-profile failure of Eli Lilly's Alzheimer's drug. Biogen shares have dropped 5.5% year-to-date, compared with a 9.9% rise in the S&P 500 .
Continue Reading Below
Copyright © 2016 MarketWatch, Inc.